As of December 31, 2024, Cogent had cash, cash equivalents and marketable securities of $287.1 million. Cogent believes this year-end balance, together with the $25.0 million gross proceeds from shares sold under the Company’s at-the-market stock offering in February 2025, will be sufficient to fund its operating expenses and capital expenditure requirements into late 2026, including through clinical readouts from the ongoing SUMMIT, PEAK and APEX registration-directed trials.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COGT:
- Cogent Biosciences reports Q4 net loss $67.9M vs. $54.4M last year
- Cogent Biosciences exec buys $332K in common stock
- Cogent Biosciences up 10% at $8.14 after disclosing insider buy
- Cogent Biosciences price target lowered to $14 from $17 at H.C. Wainwright
- Cogent Biosciences highlighted key 2025 milestones